Marrying Antibodies to RNA Therapies to Target Previously Inaccessible Tissues and Cells

Sarah Boyce, CEO of Avidity Biosciences, discusses the company’s antibody oligonucleotide conjugate platform, how its AOCs can deliver RNA therapies to tissue and cell types that were previously inaccessible, and it lead program in myotonic dystrophy type 1.